A. Mathioudakis (Manchester, United Kingdom), M. Tor (Istanbul, Turkey)
Late Breaking Abstract - Detection of clinical instability by eNose in COPD patients
J. van Bragt (Amsterdam, Netherlands), R. De Vries (Amsterdam, Netherlands), Y. Dagelet (Amsterdam, Netherlands), S. Vijverberg (Amsterdam, Netherlands), S. Kester ('s-Hertogenbosch, Netherlands), J. In 'T Veen (Rotterdam, Netherlands), E. Haarman (Amsterdam, Netherlands), A. Lucas (Eindhoven, Netherlands), F. De Jongh (Enschede, Netherlands), P. Sterk (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands)
|     |
Short Physical Performance Battery and long term prognosis following severe acute exacerbation of COPD: a prospective cohort study
R. Barker (Harefield, United Kingdom), S. Kon (London, United Kingdom), S. Jones (Harefield, United Kingdom), M. Maddocks (London, United Kingdom), W. Gao (London, United Kingdom), C. Nolan (Harefield, United Kingdom), S. Patel (Harefield, United Kingdom), H. Kwan (Kowloon, Hong Kong), S. Clarke (London, United Kingdom), M. Polkey (London, United Kingdom), P. Cullinan (London, United Kingdom), W. Man (Harefield, United Kingdom)
| |
Prognosis of COPD patients admitted to the ICU in middle income countries
M. Vukoja (Novi Sad, Republic of Serbia), M. Sabo (Rochester, United States of America), Z. Chang (Beijng, China), Y. Li (Guangzhou, China), H. Singh (New Delhi, India), O. Cakin (Antalya, Turkey), I. Kopitovic (Novi Sad, Republic of Serbia), S. Gavrilovic (Novi Sad, Republic of Serbia), A. Andrijevic (Novi Sad, Republic of Serbia), M. Hache (Santo Domingo), R. Kashyap (Rochester, United States of America), Y. Dong (Rochester, United States of America), O. Gajic (NovRochester, United States of America)
| |
Predictive value of CD14 and CD31 microparticles for the survival of COPD during 7 years
I. Ruzsics (Pécs, Hungary), . Tokés-Füzesi (Pécs, Hungary), M. Matancic (Pécs, Hungary), V. Sárosi (Pécs, Hungary), G. Woth (Pécs, Hungary), T. Molnár (Pécs, Hungary)
| |
Cluster phenotyping as an approach to identify COPD patients at risk of poor prognosis.
K. Brat (Brno, Czech Republic), M. Plutinsky (Brno, Czech Republic), V. Koblizek (Hradec Kralove, Czech Republic), J. Zatloukal (Olomouc, Czech Republic), P. Popelkova (Ostrava, Czech Republic), T. Dvorak (Mlada Boleslav, Czech Republic), P. Safranek (Pilsen, Czech Republic), D. Rakita (Prague, Czech Republic), P. Vanik (Ceske Budejovice, Czech Republic), Z. Liptakova (Ceske Budejovice, Czech Republic), L. Heribanova (Prague, Czech Republic), P. Musilova (Jihlava, Czech Republic), M. Sipkova (Liberec, Czech Republic), E. Kocova (Hradec Kralove, Czech Republic), B. Novotna (Prague, Czech Republic), O. Kudela (Hradec Kralove, Czech Republic), M. Kopecky (Hradec Kralove, Czech Republic), K. Neumannova (Olomouc, Czech Republic), M. Svoboda (Brno, Czech Republic), J. Jarkovsky (Brno, Czech Republic), Z. Zbozinkova (Brno, Czech Republic), J. Svancara (Brno, Czech Republic), J. Lnenicka (Usti nad Labem, Czech Republic), V. Rihak (Zlin, Czech Republic)
| |
Predicting hospital readmissions in severe COPD patients using an electronic-nose.
A. Rodrigo Troyano (Barcelona, Spain), J. Giner (Barcelona, Spain), D. Sousa (Buenos Aires, Argentina), J. Merino (Palma de Mallorca, Spain), A. Alonso (Barcelona, Spain), A. Feliu (Barcelona, Spain), V. Plaza (Barcelona, Spain), B. Garcia-Cosio (Palma de Mallorca, Spain), A. Agustí (Barcelona, Spain), O. Sibila (Barcelona, Spain)
| |
Vitamin-D deficiency & anaemia in patients with acute exacerbations of COPD (AECOPD); morbidity & mortality.
N. Cafferky (Sunderland, United Kingdom), H. Shah (Sunderland, United Kingdom), S. Murphy (Sunderland, United Kingdom)
| |
Neural respiratory drive (NRD) to predict long term mortality after an acute exacerbation of COPD (AECOPD)
M. Patout (Rouen, France), L. Meira (London, United Kingdom), R. D'Cruz (London, United Kingdom), G. Kaltsakas (London, United Kingdom), G. Arbane (London, United Kingdom), E. Suh (London, United Kingdom), N. Hart (London, United Kingdom), P. Murphy (London, United Kingdom)
| |
Elevated circulating MMP-9 is associated with increased exacerbation risk in COPD: results from SPIROMICS and COPDGene
J. Wells (Birmingham, United States of America), M. Parker (Boston, United States of America), R. Oster (Birmingham, United States of America), R. Bowler (Denver, United States of America), M. Dransfield (Birmingham, United States of America), S. Bhatt (Birmingham, United States of America), M. Cho (Boston, United States of America), V. Kim (Philadelphia, United States of America), J. Curtis (Ann Arbor, United States of America), F. Martinez (New York, United States of America), R. Paine (Salt Lake City , United States of America), W. O'Neal (Chapel Hill, United States of America), W. Labaki (Ann Arbor, United States of America), R. Kaner (New York, United States of America), I. Barjaktarevic (Los Angeles, United States of America), M. Han (Ann Arbor, United States of America), E. Silverman (Boston, United States of America), J. Crapo (Denver, United States of America), R. Barr (New York, United States of America), P. Woodruff (San Francisco, United States of America), P. Castaldi (Boston, United States of America), A. Gaggar (Birmingham, United States of America)
| |
Implementation of the GOLD 2017 disease classification in a real-life COPD cohort
M. Plutinsky (Brno, Czech Republic), K. Brat (Brno, Czech Republic), V. Koblizek (Hradec Kralove, Czech Republic), P. Popelkova (Ostrava, Czech Republic), J. Zatloukal (Olomouc, Czech Republic), T. Dvorak (Mlada Boleslav, Czech Republic), B. Novotna (Praha, Czech Republic), P. Vanik (Ceske Budejovice, Czech Republic), P. Musilova (Jihlava, Czech Republic), P. Safranek (Plzen, Czech Republic), L. Heribanova (Praha, Czech Republic), V. Rihak (Zlin, Czech Republic), M. Sipkova (Liberec, Czech Republic), D. Rakita (Praha, Czech Republic), E. Kocova (Hradec Kralove, Czech Republic), K. Neumannova (Olomouc, Czech Republic), M. Kopecky (Hradec Kralove, Czech Republic), O. Kudela (Hradec Kralove, Czech Republic), M. Svoboda (Brno, Czech Republic), J. Svancara (Brno, Czech Republic), Z. Zbozinkova (Brno, Czech Republic), J. Lnenicka (Usti nad Labem, Czech Republic)
| |
A service evaluation of the accuracy of the Gold Standard Framework Proactive Indicator Guidance (GSF PIG) in predicting 12 month mortality in patietns with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD).
S. Pilsworth (Liverpool, United Kingdom), D. Wat (Liverpool, United Kingdom), S. Sibley (Liverpool, United Kingdom), J. Crane (Liverpool, United Kingdom)
| |
Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations
J. Zatloukal (Olomouc, Czech Republic), E. Volakova (Olomouc, Czech Republic), V. Koblizek (Hradec Kralove, Czech Republic), M. Svoboda (Brno, Czech Republic), P. Popelkova (Ostrava, Czech Republic), M. Plutinsky (Brno, Czech Republic), K. Brat (Brno, Czech Republic), B. Novotna (Praha, Czech Republic), P. Safranek (Plzen, Czech Republic), T. Dvorak (Mlada Boleslav, Czech Republic), D. Rakita (Praha, Czech Republic), M. Sipkova (Liberec, Czech Republic), R. Simek (Zlin, Czech Republic), E. Kocova (Hradec Kralove, Czech Republic), M. Kopecky (Hradec Kralove, Czech Republic), L. Heribanova (Praha, Czech Republic), P. Musilova (Jihlava, Czech Republic), B. Snelerova (Usti nad Labem, Czech Republic), Z. Liptakova (Ceske Budejovice, Czech Republic), K. Neumannova (Olomouc, Czech Republic), Z. Zbozinkova (Brno, Czech Republic)
| |
GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients
I. Krachunov (Pleven, Bulgaria), N. Kyuchukov (Pleven, Bulgaria), Z. Ivanova (Pleven, Bulgaria), P. Hristova (Pleven, Bulgaria), P. Pavlov (Pleven, Bulgaria), P. Glogovska (Pleven, Bulgaria), T. Popova (Pleven, Bulgaria), Y. Ivanov (Pleven, Bulgaria)
| |
Impact of stable state symptoms on the future burden of COPD exacerbations
A. Mackay (London, United Kingdom), K. Kostikas (Basel, Switzerland), S. Frent (Timisoara, Romania), P. Pfister (Basel, Switzerland), P. Goyal (Basel, Switzerland), P. Gupta (Hyderabad, India), D. Banerji (East Hanover, United States of America), F. Patalano (Basel, Switzerland), J. Wedzicha (London, United Kingdom)
| |
COPD exacerbation phenotypes in a five year hospitalisation cohort
S. Brill (Lon, United Kingdom), T. Jones (Lon, United Kingdom), J. Brown (Lon, United Kingdom), J. Hurst (Lon, United Kingdom), R. Vancheeswaran (Lon, United Kingdom)
| |
Association between bacterial load and inflammatory gene expression in COPD exacerbations
H. O'Farrell (Chermside, Australia), J. Shaw (Chermside, Australia), R. Bowman (Chermside, Australia), K. Fong (Chermside, Australia), I. Yang (Chermside, Australia)
| |
Impact of moderate and severe exacerbations in severe COPD patients
N. Gunsoy (Uxbridge, United Kingdom), K. Pascoe (Brentford, United Kingdom), Y. Asukai (Brentford, United Kingdom), C. Gait (Uxbridge, United Kingdom), D. Galkin (NC, United States of America)
| |
VALIDATION OF AN ASSESSMENT TOOL FOR CONTROL IN COPD: ANALYSIS OF CLINICAL VARIABLES.
P. Catalan Serra (Valencia, Spain), B. Alcázar (Granada, Spain), M. Miravitlles (Barcelona, Spain), M. Marzo (Valencia, Spain), J. Soler-Cataluña (Valencia, Spain)
| |